Trial Profile
A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms DEEPER
- 20 Jan 2024 Results(n=137) investigating the association between GWMS and clinical outcomes of first-line chemotherapy with anti-EGFR or anti-VEGF antibody agents for metastatic colorectal cancer, presented at the 2024 Gastrointestinal Cancers Symposium
- 24 Oct 2023 Results of an updated survival analysis performed using BRAF status added by tumor tissue biomarker analysis presented at the 48th European Society for Medical Oncology Congress
- 16 Oct 2023 According to a Merck & Co media release, data of this study will be presented at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting